Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APB-R3 SAD in Healthy Participants
NCT05715736Phase 1Completed
- Sponsor
- Syneos Health
- Start
- Mar 2023
- Primary completion
- Dec 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EVO301 in adult-onset Still's disease (AOSD) (2 arms), sponsored by Syneos Health. Primary endpoint: Safety and Tolerability of APB-R3 up to 92 days. Started Mar 2023; status: completed.
02
Drugs
EVO301
03
Conditions
adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on NCT05715736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05715736.